The CJC-1295 + Ipamorelin combination is one of the most widely studied growth hormone secretagogue stacks in the peptide research literature. The rationale is mechanistically elegant: the two compounds engage complementary receptor systems on pituitary somatotrophs, producing synergistic GH release that exceeds what either compound achieves alone — while maintaining a physiologically pulsatile pattern that mimics natural GH secretion.
Growth hormone release from the pituitary is regulated by two main signals from the hypothalamus:
Both receptors are present on the same pituitary somatotroph cells, but they activate GH release through distinct intracellular signaling pathways. When both are activated simultaneously, the result is amplified GH secretion compared to activation of either receptor alone — a pharmacological synergy that has been reproducibly demonstrated across multiple research models.
CJC-1295 is a 29-amino acid synthetic GHRH analog with four substitutions conferring proteolytic resistance over native GHRH (half-life ~30 minutes for the standard form vs <7 minutes for native GHRH). The Drug Affinity Complex (DAC) version covalently binds serum albumin for a half-life of 6–8 days, though researchers typically use the non-DAC form for pulse-pattern studies.
Teichman et al. (JCEM, 2006): CJC-1295 produced dose-dependent, sustained GH and IGF-1 elevation in healthy adults. The DAC version elevated mean GH levels for up to 28 days post-injection, with IGF-1 increases maintained throughout — demonstrating robust and durable GH-axis stimulation from a single compound. J Clin Endocrinol Metab, 2006.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed by Novo Nordisk in the late 1990s. Its key pharmacological distinction from earlier GH secretagogues like GHRP-2 and GHRP-6 is high selectivity for GH release without significant cortisol, prolactin, or ACTH elevation. This "clean" profile makes it preferable for research where GH axis effects need to be studied without confounding hormonal activation.
GHRP-2 and GHRP-6 both stimulate significant cortisol and prolactin release alongside GH — making it difficult to attribute observed experimental outcomes specifically to GH versus stress hormone effects. Ipamorelin's selectivity eliminates this confound, providing a cleaner pharmacological tool for GH-axis research.
Bowers et al. (receptor characterization): Foundational characterization of Ipamorelin's GHSR-1a binding profile confirmed GH selectivity at doses 10–100× higher than those required for GH release — confirming clean selectivity as a core pharmacological property. Multiple publications, Novo Nordisk research group.
The synergy between GHRH analogs and ghrelin receptor agonists is one of the most reproducible findings in GH secretagogue research. Studies consistently show 2–5× amplification of GH pulse amplitude when GHRH analogs and GHRPs/Ipamorelin are combined versus either compound alone. Proposed mechanisms include:
Both verified by third-party HPLC · Lot-specific COA · US domestic shipping
Shop GH Secretagogues →